TY  - CHAP
M1  - Book, Section
TI  - Inflammatory Bowel Disease
A1  - Hemstreet, Brian A.
A2  - DiPiro, Joseph T.
A2  - Yee, Gary C.
A2  - Haines, Stuart T.
A2  - Nolin, Thomas D.
A2  - Ellingrod, Vicki L.
A2  - Posey, L. Michael
PY  - 2023
T2  - DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 12th Edition
AB  - Update  SummaryFebruary  1,  2023The  following  sections,  tables,  and  figures  were  updated:Key  Concepts:  upadacitinib  added  to  key  concept  8,  and  rizankizuman-rzaa  added  to  key  concept  11Beyond  The  Book:  part  d  revisedFigure  52-2:  risankizumab-rzaa  addedTable  52-4:  rizankizumab-rzaa  and  upadacitinib  addedFigure  52-3:  updated  based  on  new  guidelines  to  include  new  therapiesTable  52-5:  upadacitinib  and  rizankizumab-rzaa  addedAdverse  Drug  Effects:  edits  made  to  include  upadacitinib  and  risankizumab-rzaaSpecial  Populations,  Pregnancy,  and  Breastfeeding:  information  added  for  upadacitinib  and  risankizumab-rzaa  
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/04/16
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1205566115
ER  -